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ABSTRACT
DELDICQUE, L., M. LOUIS, D. THEISEN, H. NIELENS, M. DEHOUX, J.-P. THISSEN, M. J. RENNIE, and M. FRANCAUX.
Increased IGF mRNA in Human Skeletal Muscle after Creatine Supplementation. Med. Sci. Sports Exerc., Vol. 37, No. 5, pp. 731–736,
2005. Purpose: We hypothesized that creatine supplementation would facilitate muscle anabolism by increasing the expression of
growth factors and the phosphorylation of anabolic signaling molecules; we therefore tested the responses of mRNA for IGF-I and
IGF-II and the phosphorylation state of components of anabolic signaling pathways p70s6k and 4E-BP1 to a bout of high-intensity
resistance exercise after 5 d of creatine supplementation. Methods: In a double-blind cross-over design, muscle biopsies were taken
from the m. vastus lateralis at rest and 3 and 24 h postexercise in subjects who had taken creatine or placebo for 5 d (21 g·d1). For
the first 3 h postexercise, the subjects were fed with a drink containing maltodextrin (0.3 g·kg1 body weight·h1) and protein (0.08
g·kg1 body weight·h1). Results: After creatine supplementation, resting muscle expressed more mRNA for IGF-I (30%, P 0.05)
and IGF-II (40%, P  0.054). Exercise caused an increase by 3 h postexercise in IGF-I (24%, P  0.05) and IGF-II (48%, P
 0.05) and by 24 h postexercise in IGF-I (29%, P  0.05), but this effect was not potentiated by creatine supplementation. The
phosphorylation states of p70s6k and 4E-BP1 were not affected by creatine at rest; phosphorylation of both increased (150–400%, P
 0.05) to similar levels under placebo and creatine conditions at 3 h postexercise plus feeding. However, the phosphorylation state
of 4E-BP1 was higher in the creatine versus placebo condition at 24 h postexercise. Conclusion: The increase in lean body mass often
reported after creatine supplementation could be mediated by signaling pathway(s) involving IGF and 4E-BP1. Key Words:
RESISTANCE EXERCISE, PROTEIN SYNTHESIS, P70S6K, 4E-BP1, REAL-TIME RT-PCR
Over the last 15 yr, the use of creatine as an ergogenicaid has increased markedly, especially amongstrength and power athletes. Surprisingly, creatine
supplementation has been found not only to increase the
short-term power output during high-intensity exercises but
to result in significant increases in lean body, particularly
muscle mass (3). There is evidence that this increase is
mainly intracellular, suggesting that the cell dry mass is
increased (8). Additionally, a number of workers have found
increases in muscle fiber area (26,27,29). Taken together,
these observations suggest that creatine could enhance mus-
cle growth by stimulating protein synthesis.
In previous studies (14,15) we set out to discover
whether 5 d of oral creatine supplementation could po-
tentiate protein synthesis in human muscle. We could not
confirm this hypothesis either at rest in the postabsorptive
or fed state, or at rest after an acute bout of resistance
exercise. These results could be interpreted in several
ways. First, it is possible that creatine has no anabolic
effect on muscle, which would, however, not be in line
with previous observations (see above). Second, creatine
might have an effect but beyond the time frame of our
previous experiments (3.5 h). Third, the effect of cre-
atine could be small and below the detection limits of our
previously used methods.
Insulinlike growth factor I (IGF-I) is known to increase
muscle protein synthesis and to stimulate satellite cell pro-
liferation and differentiation in vitro (1). Recently, we
showed that myogenic C2C12 cells incubated with creatine
differentiated more rapidly than in control conditions; this
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observation was associated with an increase in IGF-I mRNA
expression (16).
IGF-II, another member of the IGF family, is also pro-
duced by skeletal muscle and is involved in muscle differ-
entiation and regeneration (12). IGF activate several cellular
pathways regulating muscle atrophy and hypertrophy, in-
cluding the PI3K-Akt/PKB-mTOR signaling pathway (24).
The PI3K-Akt/PKB-mTOR pathway is involved in the
regulation of skeletal muscle fiber size and in the stimula-
tion of translation initiation by activating mTOR and two of
its downstream effectors: p70s6k and 4E-BP1 (eukaryotic
initiation factor-4e binding protein-1) also called PHAS-I
(phosphorylated heat- and acid-stable protein regulated by
insulin). p70s6k and 4E-BP1 are two key regulators of pro-
tein synthesis. p70s6k phosphorylates the ribosomal phos-
phoprotein S6 on the 40S subunit (20). S6 is involved in the
translation of a class of mRNA called TOP mRNAs (due to
their terminal region rich in oligopyrimidines). This class of
mRNA encodes for components of the translational machin-
ery and elongation factors (11). The phosphorylation state of
p70s6k and consequently its activity are increased by amino
acids, insulin, and exercise (23).
4E-BP1, a translational repressor (6), can bind to the
initiation factor eIF4E to prevent the formation of the eIF4F
scaffolding complex, which is necessary for efficient bind-
ing of the 40S ribosomal subunit to mRNA. When 4E-BP1
is hyperphosphorylated, it dissociates from eIF4E allowing
it to participate in translation initiation. In human skeletal
muscle, 4E-BP1 is activated by branched chain amino acid
infusion (13) and exercise (21).
Because we previously could not demonstrate an acute
increase in protein synthesis after creatine ingestion (14,15),
we hypothesized that creatine has a measurable effect on
downstream regulatory factors from the PI3K-Akt/PKB-
mTOR pathway and that it could act upstream, in a longer
time frame, via the IGF. Therefore, the aim of the present
study was to test the prediction that creatine supplementa-
tion alone would enhance IGF-I and IGF-II gene expression,
and increase the phosphorylation state of p70s6k and 4E-
BP1. Furthermore, we speculated that high-intensity resis-
tance exercises would potentiate these effects.
MATERIALS AND METHODS
Subjects and Study Design
Six healthy young men (age 23 0.6 yr, body mass 77.1
5.1 kg, height 186  1.0 cm) who were physically active but
not specifically trained for resistance exercises participated in
this double-blind, cross-over study. All subjects were given an
oral and written account of the study before signing an in-
formed consent form. This study was approved by the ethics
committee of the Universite´ Catholique de Louvain, and all the
procedures used were in accordance with the Declaration of
Helsinki. The subjects were randomly divided into two groups:
one group (N 3) received 21 g of oral creatine monohydrate
per day for 5 d, whereas the second group (N  3) received a
placebo (maltodextrin 21 g). After a washout period of 1
month, the treatments were crossed over.
Protocol
During an initial familiarization session 1 wk before the
main study, each subject completed a leg-press test with one
leg to determine the one-repetition maximum (1-RM). The
subjects were free to choose their preferred leg for exercise,
but they were asked to use the same leg subsequently for
both the creatine and placebo trials.
The day before and the day of the experiment, the sub-
jects were asked not to participate in any sport activities and
to maintain their usual diet. On the day of testing, subjects
reported to the laboratory at 8.00 a.m. after an overnight
fast, and a muscle biopsy was taken at rest from the vastus
lateralis. Subsequently, subjects received a standardized
meal (two croissants (2  60 g) and one glass of orange
juice (200 mL)), after which they began the exercise session.
They first warmed up with three sets of 10 repetitions on the
leg press. The subsequent exercise test consisted of 10 sets
of 10 leg-press repetitions (every 5 s) at 70% of each
individual 1-RM. The sets were interspersed with 2-min rest
periods, and the subjects received verbal encouragement
throughout the exercise session. During the first hour pos-
texercise, the subjects ingested a drink containing 0.3
g·kg1 body weight·h1 maltodextrin (Nestle´; Caloreen,
Brussels, Belgium) and 0.08 g·kg1 body weight·h1
skimmed milk protein powder (Nutricia; Protifar Plus,
Bornem, Belgium) dissolved in water. A second muscle
biopsy was taken 3 h postexercise from the exercised leg
(with the subjects in the fed state), and a third biopsy was
taken the following day, 24 h postexercise, in the fasted
state. All the biopsies were taken from the midportion of the
vastus lateralis muscle with a 4-mm Bergstro¨m biopsy nee-
dle after local anesthesia with 1% lidocaine. Blood, macro-
scopically visible fat, and connective tissue were quickly
removed, and the sample was immediately frozen in liquid
nitrogen and stored at 80°C for later analysis.
RNA Extraction and Quantitative Real-Time PCR
Total RNA was prepared from frozen tissue samples (90
mg) using TRIZOL® (Gibco Life Technologies, Paisley,
UK). RNA was quantified by spectrophotometry (  260
nm), and its concentration adjusted to 1 g·L1 using
RNase-free water. Reverse transcription (RT) was per-
formed using the GeneAmp PCR system 2400 (Applied
Biosystems, Foster City, CA) with 1 g of total RNA in a
reaction volume of 20 l, containing 7.5 M random hex-
amers, RT buffer 1X, 9 mM dithiothreitol, 220 M of each
TABLE 1. Sequences of primers used for mRNA quantification by real-time RT-PCR.
Primer Name Sequence (5 to 3) Accession No.
-2-globulin Fw gga ggc tat cca gcg tac tcc NM_004048
-2-globulin Rv cgg atg gat gaa acc cag ac
IGF-I Fw atc agc agt ctt cca acc caa NM_000618
IGF-I Rv cag cgc cag gta gaa gag atg
IGF-II Fw agc ttg ttg aca cgc ttc agt NM_000612
IGF-II Rv tgc cct ctc tca act ctt tga
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deoxyribonucleotide triphosphate (dNTP), 20 U ribonucle-
ase inhibitor (Applied Biosystems), and 50 U of reverse
transcriptase (Superscript®, Gibco, BRL). The final RT
product was adjusted to 40 L using RNase free water.
Real-time RT-PCR (reverse transcription–polymerase chain
reaction) primers were designed (Table 1, Primer Express
Software, Applied Biosystems) for human IGF-I, IGF-II,
and -2-microglobulin. The latter was used as the “house
keeping” gene, because preliminary experiments as well as
a previous study (19) had revealed that it was not affected by
either exercise or creatine supplementation. In the current
study, the intrasubject coefficient of variation (CV) of the
threshold cycle (Ct) values varied between 0.9 and 3.9%.
Sybr Green® real-time RT-PCR analyses were carried out
on the GeneAmp 5700 (Applied Biosystems) using the
following cycle conditions: 10 min at 95°C, followed by 40
cycles of 1 min at 60°C and 15 s at 95°C. For each gene,
real-time RT-PCR was conducted in duplicate with a 25-L
reaction volume of 5 ng of cDNA, 2.5-L Sybr Green®
buffer, 250 M dNTP, 3 mM MgCl2, 400 nM of each
primer, and 0.625 U AmpliTaq Gold® DNA Polymerase
(Applied Biosystems). To ensure the quality of the mea-
surements, each plate included, for each gene, a negative
control (sample replaced by RNase free water) and a posi-
tive control consisting of an aliquot from a mixed pool of
cDNA of positive samples. Ct from a positive sample was
used to calculate the interassay CV. For each gene, the CV
was calculated as standard deviation/mean of the 2 Ct de-
termined on five different plates and with different mixes.
Typically, the CV obtained was  5%. The mRNA results
are presented as Ct: Ctgene of interest  Cthouse keeping gene.
Western Immunoblotting Techniques
p70S6k. About 20 mg of frozen muscle were ground in a
mortar and homogenized in ice-cold buffer (20 mM Tris, pH
7.0, 0.27 M sucrose, 5 mM EGTA, 1 mM EDTA, 1% Triton
X-100, 1 mM sodium orthovanadate, 50 mM sodium
-glycerophosphate, 5 mM sodium pyrophosphate, 50 mM
sodium fluoride, 1 mM 1,4-dithiothreitol (DTT), and a pro-
tease inhibitor cocktail containing 1 mM EDTA (Roche
Applied Science, Mannheim, Germany)) (25). The homog-
enate was immediately centrifuged at 10,000 g for 10 min
at 4°C. The supernatants were stored in liquid nitrogen.
Protein concentration was determined using the DC protein
assay kit (Bio-Rad Laboratories, Hercules, CA).
Cell lysates (40 g of protein) were combined with Lae-
mmli sample buffer and separated by SDS-PAGE (sodium
dodecylsulfate polyacrylamide gel electrophoresis) using an
8% gel. After electrophoretic separation at 40 mA, the proteins
were transferred at 80 V for 90 min to a PVDF membrane
(Amersham Biosciences, Uppsala, Sweden) for Western anal-
ysis. All membranes were incubated for the same time and in
the same conditions. Membranes were incubated for 2 h in a
5% Blotto solution (5% powdered milk in Tris buffer saline
with 0.01% Tween-20, TBST) containing 50 mM NaF to
inhibit phosphatases. The blocking solution was then poured
off. The phospho-specific p70s6k antibody (1:1000) [(Thr389),
Santa Cruz Biotechnology, Santa Cruz, CA] was added and
incubated overnight at 4°C in Blotto containing 50 mM NaF.
Membranes were washed (3  10 min) in TBST and then
incubated for 1 h at room temperature in secondary antibody
conjugated to horseradish peroxidase (1:10,000) (Calbiochem,
San Diego, CA) in a 5% Blotto solution. After an additional
three washes in TBST, chemiluminescent detection was carried
out using an ECL Western blotting kit (Amersham Bio-
sciences). As a loading control, membranes were then stripped
and reprobed with an anti-p70s6k (1:1000) (Santa Cruz Bio-
technology) that recognizes both phosphorylated and nonphos-
phorylated forms. Total p70s6k was found to be unchanged by
creatine and exercise. The films were scanned on an ImageS-
canner using the Labscan Software and quantified with the
Image Master 1D Image Analysis Software (Amersham
Biosciences).
4E-BP1. Muscle samples were treated as described by
Xu et al. (30). About 20 mg of muscle were homogenized in
ice-cold buffer (50 mM sodium -glycerophosphate, pH
7.3, 100 mM sodium fluoride, 5 mM EDTA, 2 mM EGTA,
0.1 mM sodium orthovanadate, 1 mM benzamidine, 10
g·mL1 leupeptin, and 0.2 mM phenylmethylsulfonyl flu-
oride). The homogenate was centrifuged at 10,000  g for
20 min at 4°C. The supernatant was heated at 100°C for 10
min and was then centrifuged at 10,000  g for 30 min at
4°C. The supernatants were stored in liquid nitrogen for
further analysis. The proteins were combined with Laemmli
sample buffer and separated on a 15% gel by SDS-PAGE.
Proteins were transferred to a PVDF membrane. After in-
cubation in a 5% Blotto solution, PHAS-I antibody (1:1000)
(Calbiochem) was added and incubated overnight at 4°C.
Membranes were then treated as described above.
Muscle Creatine
A fraction of the initial muscle biopsy (30 mg) was used
for spectrophotometric determination of total creatine (i.e.,
creatine phosphate  free creatine). Ground muscle was
extracted in 0.25 N HClO4 and neutralized with 1 N KOH.
To hydrolyze creatine phosphate, 2 N HCl was added to the
supernatant, which was then heated for 15 min at 60°C. The
reaction was stopped on ice and the supernatant neutralized
with 2 N NaOH. Total creatine was immediately determined
enzymatically using a spectrophotometric method described
by Guder et al. (9) (Creatinine PAP, Boerhinger Mannheim,
Germany, from which the creatininase was omitted).
Statistics
Results are expressed as means  SEM. A repeated
measures ANOVA design was used to assess the statistical
significance of differences between mean values over time
and between conditions. Dunnett’s pairwise multiple com-
parison t-test was used as post hoc test to compare postex-
ercise with control resting conditions. The threshold of
significance was set at 0.05.
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RESULTS
Muscle Total Creatine
Muscle total creatine concentration increased from 113
7 mol·g1 dry weight to 141  10 mol·g1 dry weight
(P  0.05) as a result of the creatine supplementation.
IGF-I and IGF-II mRNA
Real-time RT-PCR. Resting human skeletal muscle
expressed IGF-I and IGF-II mRNA. Based on Ct values,
IGF-I mRNA was less abundant, about one half, than IGF-II
(data not shown).
IGF-I. In the placebo condition, heavy-resistance exer-
cise increased IGF-I mRNA by 3 h postexercise (24%, P 
0.05), which was maintained 24 h postexercise (29%, P 
0.05, Fig. 1A). After 5 d of creatine supplementation, IGF-I
mRNA expression at rest was increased by 30% (P 0.05),
but exercise had no further effect on this. The mRNA
expression measured after exercise was similar for the cre-
atine supplemented and the placebo conditions.
IGF-II. Under placebo, IGF-II mRNA level was in-
creased by 48% at 3 h postexercise (P 0.05), and returned
to values similar to rest 24 h postexercise (Fig. 1B). Creatine
supplementation upregulated the expression of IGF-II
mRNA at rest (46%), although the statistical threshold was
not reached (P  0.054) due to the variability induced by
one of the six subjects. In creatine-supplemented subjects,
IGF-II mRNA expression dropped 20% 3 h and 24 h after
exercise, but these values were not statistically different
from rest condition.
Phosphorylation state of p70s6k and 4E-BP1
p70s6k. Three hours postexercise plus feeding, the phos-
phorylation state of p70s6k increased by about 400% both in
the placebo (P  0.001) and creatine conditions (P  0.05,
Fig. 2A). The phosphorylation state of p70s6k returned to
basal values 24 h postexercise. Creatine had no additional
effect on the phosphorylation state of p70s6k.
4E-BP1. In the placebo condition, the fraction of 4E-
BP1 in the gamma form was approximately doubled 3 h
postexercise (P  0.05, Fig. 2B). It also increased 1.5-fold
in the creatine condition, but the significance threshold was
not reached (P 0.06). Twenty-four hours postexercise, the
FIGURE 1—mRNA level of IGF-I (A) and IGF-II (B) in placebo and
creatine conditions at rest and after exercise. Symbols above histo-
grams depict significant differences with rest under the same treat-
ment; *P < 0.05.
FIGURE 2—Changes in the phosphorylation state of p70s6k (A) and
4E-BP1 (B) in placebo and creatine conditions at rest and after exer-
cise. Symbols above histograms depict significant differences with rest
under the same treatment; *P < 0.05; ***P < 0.001.
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phosphorylation state of 4E-BP1 displayed a slight decrease
toward basal values. It was not affected by creatine at rest
and at 3 h postexercise, but remained more elevated, and
thus different from placebo, at 24 h postexercise (P 0.05).
DISCUSSION
Recently, we observed that creatine added to the culture
medium of myogenic cells (C2C12) improved cell differen-
tiation and increased expression of the IGF-I mRNA (16). In
the present study, we hypothesized that expression of IGF
would also be increased in human skeletal muscle after 5 d
of creatine supplementation. Indeed, the amount of IGF-I
was higher in resting muscle after creatine intake, and
IGF-II mRNA showed an increasing trend (Fig. 1). Al-
though the increases in IGF mRNA were only 30–40%,
they may help to enhance the anabolic milieu in skeletal
muscle, which could explain the increase in muscle mass
reported after creatine supplementation (see below) (3,8).
Exercise did not induce a further change in IGF-I and
IGF-II mRNA when the subjects were supplemented with
creatine (Fig. 1, A and B). This indicates that both exercise
and creatine increase the expression of IGF, but that these
effects are not cumulative.
Even though the design of the present study does not
enable us to distinguish the confounding effects of exercise
and feeding at 3 h postexercise, a 20% increase in IGF
mRNA was observed 3 h and 24 h after a session of
resistance exercise. Bamman et al. (4) already reported a
62% increase in IGF-I mRNA after a bout of eccentric
exercises at 110% of the 1-RM and a trend to upregulation
after concentric exercises at 85% of the 1-RM. The results
of the present study (24%) compare well with the data
reported by those authors because the leg-press exercise was
performed against a load equal to 70% of the 1-RM. On the
other hand, the effect of creatine in the resting condition
reached similar range of increase (30%). The upregulation
of IGF-I mRNA could be a mechanism by which exercise
and creatine exert their effect on muscle hypertrophy.
Whereas evidence linking muscle activity and local IGF-I
and IGF-II availability is growing, the mechanism by which
muscle overload modulates IGF-I and IGF-II expression is
unclear. In mammals, the IGF-I gene consists of six exons
with several regulating promoters (10). In skeletal muscle,
IGF-I transcription appears to be mostly regulated by the
exon 1 promoter, which is activated by MyoD and the
calcium signaling molecule calcineurin (17).
Once bound to their common receptor, IGF can stimulate
several signaling pathways, among others the PI3K-Akt/
PKB-mTOR pathway (7), which plays an important role in
the regulation of muscle hypertrophy. The PI3K-Akt/PKB-
mTOR pathway and its downstream targets p70s6k and 4E-
BP1 can also respond to other signals such as exercise and
feeding. In rats, the activation of this pathway after exercise
is rapid and large, more than double in a few minutes (5).
Thus, in contrast to the delayed-response regulation by IGF,
exercise and feeding induce an early response at the level of
p70s6k and 4E-BP1, comparable to an on/off switch (22), as
confirmed by the present results. Phosphorylation of p70s6k
was measured using an antibody recognizing phosphory-
lated Thr 389, which corresponds to the highest level of
phosphorylation of p70s6k and its highest activity (28). The
phosphorylation state of p70s6k increased fourfold 3 h post-
exercise (Fig. 2A) in accordance with previous studies on
rats (2). Six hours after high-resistance lengthening contrac-
tions, the activity of p70s6k in rats was tripled, and the
phosphorylation of p70s6k correlated with increased skeletal
muscle mass after 6 wk of training (2). Creatine ingestion
did not potentiate the phosphorylation of p70s6k in the
present study.
The effect of exercise on 4E-BP1 has been less exten-
sively investigated. In our study, exercise doubled the
gamma form of 4E-BP1, which is the most phosphorylated
form of the protein (18) (Fig. 2B). No supplementary effect
of creatine was found 3 h postexercise. However, the
gamma form of 4E-BP1 remained more elevated than in the
placebo condition 24 h postexercise. The activation of 4E-
BP1 by phosphorylation results in its release from eIF4E
and allows the latter to participate in the initiation of protein
synthesis by enabling the formation of the eIF4F complex.
The dissimilar effects of creatine on 4E-BP1 and p70s6k
are surprising because both proteins are downstream targets
of the same pathway. Nevertheless, other involved factors,
like the protein phosphatase 2A and/or a crosstalk between
the MEK/MAPK pathway and p70s6k, cannot be excluded
and may explain the difference. Creatine could have a more
direct effect on 4E-BP1 and maybe not on p70s6k. Clearly,
further research is warranted to clarify these issues.
In summary, creatine supplementation had no potentiat-
ing effect on the activation of p70s6k and 4E-BP1 3 h after
acute exercise. As already pointed out, the increase in the
phosphorylation state of p70s6k and 4E-BP1 after 3 h was
not due to exercise alone but was induced by both acute
exercise (5) and feeding (13). These observations are in
accordance with our previous finding that in comparable
conditions, creatine did not enhance protein synthesis within
a short time frame (14,15). Creatine increased the expres-
sion of IGF-I only at rest with no additional effect of
exercise. The phosphorylation state of 4E-BP1 was also
found to be more elevated 24 h postexercise. Our results
indicate that creatine supplementation could act to stimulate
muscle growth, but not by a rapidly responding control
system as observed after exercise plus feeding, but rather by
a late-response enhancement of the anabolic status of the
cell involving IGF.
This work is granted by the “Fonds de la Recherche Scientifique
Me´dicale” (3.4574.03), Belgium.
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